Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.90 |
| ▸ | CA4 | P22748 | 4/20 | 0.61 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27463338 | 1.00 | CA1 (0.90) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL29035496 | 1.00 | CA1 (0.90) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL3630520 | 1.00 | CA1 (0.90) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL28668866 | 1.00 | CA1 (0.90) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL29008905 | 1.00 | CA1 (0.90) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL449428 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL7568296 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL28859803 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL11768103 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL1987748 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119595804-A | Method for detecting content of heparin precursor and application thereof | 深圳市天道医药有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-109613157-A | A kind of raw material heparin sodium for producing Enoxaparin Sodium and using | 山东万邦赛诺康生化制药股份有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-1753624-B | Method for reducing acrylamide formation in thermally processed foods | FRITO LAY NORTH AMERICA INC FO | 2010-05-12 | — | — | CN | claimed |
| CN-1753624-A | Method for reducing acrylamide formation in thermally processed foods | FRITO LAY NORTH AMERICA INC FO (US) | 2006-03-29 | — | — | CN | claimed |
| CN-116218827-B | Heparanase mutant and recombinant expression method and application thereof | 深圳大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-116256455-B | Method for identifying bovine pulmonary heparin doping content in porcine intestinal mucosa derived heparin | 东营天东制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119595804-A | Method for detecting content of heparin precursor and application thereof | 深圳市天道医药有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-115927277-B | Heparanase mutant H1-6 and engineering strain and application thereof | 深圳大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-115851669-B | Heparanase mutant H1-5 and encoding gene, mutant strain and application thereof | 深圳大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-116218826-B | Heparanase mutant H2-15 and engineering strain and application thereof | 深圳大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-116577428-A | Method for detecting enoxaparin sodium heparinase II enzymatic hydrolysis component | 东营天东制药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116256455-A | Method for identifying bovine pulmonary heparin doping content in porcine intestinal mucosa derived heparin | 东营天东制药有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-110840914-A | Method for alleviating or improving vascular disorders using cell therapeutic agent | 博雅干细胞科技有限公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-109613157-A | A kind of raw material heparin sodium for producing Enoxaparin Sodium and using | 山东万邦赛诺康生化制药股份有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-107468644-A | A kind of levo-oxiracetam injection and preparation method thereof | 重庆润泽医药有限公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-107028897-A | Immunomodulator thymopeptide-5 powder-injection pharmaceutical composition and quality control method | 北京元延医药科技股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-102743379-B | Composition containing eighteen amino acids and preparation method thereof | LI HUI | 2013-07-31 | — | — | CN | disclosed |
| CN-102743379-A | Composition containing eighteen amino acids | LI HUI | 2012-10-24 | — | — | CN | disclosed |
| CN-1753624-B | Method for reducing acrylamide formation in thermally processed foods | FRITO LAY NORTH AMERICA INC FO | 2010-05-12 | — | — | CN | disclosed |
| CN-1753624-A | Method for reducing acrylamide formation in thermally processed foods | FRITO LAY NORTH AMERICA INC FO (US) | 2006-03-29 | — | — | CN | disclosed |